Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HDM1002 in T2DM
NCT06481085Phase 2Completed
- Sponsor
- Huadong Medicine
- Start
- Jun 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of conveglipron in type 2 diabetes mellitus (T2DM), sponsored by Huadong Medicine. Started Jun 2024; status: completed.
02
Drugs
conveglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06481085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481085.